Sarepta to Expedite Timeline for Muscular Dystrophy Gene Therapy

Sarepta to Expedite Timeline for Muscular Dystrophy Gene Therapy

Source: 
BioSpace
snippet: 

In its second-quarter conference call, Sarepta Therapeutics indicated plans to accelerate its timeline for SRP-9001 (delandistrogene moxeparvovec), a gene therapy for Duchenne muscular dystrophy (DMD).